Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to…
$12.76-27.62%
报价 2026-11-09
市值
$780.1M
EV
$835.1M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -63.3%
$12.18$34.74
筛选结果
pipeline · 2026-11-09Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-09不在筛选范围：industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| JANXJanux Therapeutics, Inc. | $780.1M | -27.6% | +198.0% | 47.2% | – | – | – | |
| ABCLAbCellera Biologics Inc. | $4.05B | +5.2% | – | 75% | – | – | – | |
| CLDXCelldex Therapeutics, Inc. | $2.45B | +4.6% | -37.0% | 100% | – | – | – | |
| BHVNBiohaven Ltd. | $2.3B | +5.2% | +55466.7% | 0% | – | – | – | |
| IMNMImmunome, Inc. | $2.28B | +3.5% | -96.1% | -1,161.9% | – | – | – | |
| ZYMEZymeworks Inc. | $2.22B | +4.0% | – | 98.4% | – | – | – | |
| VERAVera Therapeutics, Inc. | $2.21B | +2.8% | +124.8% | 0% | – | – | – | |
| HRMYHarmony Biosciences Holdings, Inc. | $1.97B | +2.0% | +18.9% | 77.2% | 10.0x | 4.3x | 6.1x | |
| MAZEMaze Therapeutics, Inc. | $1.94B | +2.1% | +545.2% | 95.3% | – | – | – | |
| 同行中位数 | – | – | +71.8% | 76.1% | 10.0x | 4.3x | 6.1x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。